All In MedTech

FDA Clearance Tracker · P990004-S028

SURGIFOAM ABSORBABLE GELATIN SPONGE, USP

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 5, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 5, 2016

Approved

Time to decision

336 days

Received Mar 6, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P990004-S028
Device name
SURGIFOAM ABSORBABLE GELATIN SPONGE, USP
Applicant location
Soeborg
Received
Mar 6, 2015
Decided
Feb 5, 2016
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P990004

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMF

FDA's approval statement

As written in FDA's record.

approval for a manufacturing site located at SteriPack Medical Poland SP.ZO.O., Poland, for the contract packaging of the SURGIFLO Hemostatic Matrix Device and thesterilizing site located at Synergy Health Ede BV, Netherlands, for the sterilization of theSURGIFLO Hemostatic

Source documents

Other decisions for Ferrosan Meidcal Devices A/S

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.